Accretion Pharmaceuticals Limited, a Gujarat based pharmaceutical company, has launched its Initial Public Offering (IPO) on May 14, 2025. The IPO is scheduled to close on May 16, 2025.
Accretion Pharmaceuticals IPO Overview
Established in 2012, Accretion Pharmaceuticals Limited specializes in the manufacturing and sale of a diverse range of healthcare products, including:
- Tablets and Capsules
- Oral Liquids and Syrups
- External Preparations (Ointments, Creams, Gels, Lotions, Medicated Shampoos, Mouthwashes, Dusting Powders)
- Oral Powders (Sachets and Dry Syrups)
- Ayurvedic and Herbal Products
The company also offers contract manufacturing services and operates its manufacturing facility in Ahmedabad, Sanand, Gujarat.
Accretion Pharmaceuticals IPO Details
Accretion Pharmaceuticals IPO is a bookbuilding IPO of Rs 29.75 crores. The issue is a complete fresh issue of Rs 29.75 crores. Jawa Capital Services Private Limited is the book running lead manger of the Accretion Pharmaceuticals IPO, Kfin Technologies Limited is the Registrar for the issue. Market Maker for Accretion Pharmaceuticals IPO is Gretex Share Broking Private Limited.
| Issue Type | Bookbuilding IPO |
| Face Value | Rs 10 per share |
| Issue Price | Rs 96 – 101 per share |
| Lot Size | 1200 shares per lot |
| Issue Size | Rs 29.75 crore |
| Fresh Issue | Rs 29.75 crore |
| Offer for Sale (OFS) | Rs 0 crore |
| Listing at | NSE SME |
| Market Capitalization | Rs 112.27 cr |
| Book Running Lead Managers | Jawa Capital Services Private Limited |
| Registrar | Kfin Technologies Limited |
| Market Maker | Gretex Share Broking Private Limited |
Accretion Pharmaceuticals IPO Timeline
Accretion Pharmaceuticals IPO opens on 14th May 2025 and Closes on 16th May 2025. Find Accretion Pharmaceuticals IPO tentative dates below.
| IPO Open Date | 14-May-2025 (Wednesday) |
| IPO Close Date | 16-May-2025 (Friday) |
| Allotment | 19-May-2025 (Monday) |
| Initiation of Refunds | 20-May-2025 (Tuesday) |
| Demat Credit of Shares | 20-May-2025 (Tuesday) |
| Listing Date | 21-May-2025 (Wednesday) |
| Cut off time for UPI mandate confirmation | 16-May-2025 at 5PM |
Accretion Pharmaceuticals IPO Lot Size
Investors can bid for a minimum of 1200 shares and in multiples thereof. The following table shows the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Minimum) | 1 | 1200 | Rs 1,21,200 |
| Retail (Maximum) | 1 | 1200 | Rs 1,21,200 |
| HNI (Minimum) | 2 | 2400 | Rs 2,42,400 |
Accretion Pharmaceuticals IPO Objectives
The proceeds from the Accretion Pharmaceuticals IPO will be utilized for following purposes:
| Purpose | Amount (in Rs) | Percentage |
|---|---|---|
| Capital Expenditure for acquiring new equipment and machinery | 2.69 Crore | 9.04% |
| Facility Upgradation for enhancing the existing manufacturing facility | 4.65 Crore | 15.63% |
| Debt Repayment | 0.99 Crore | 3.33% |
| Working Capital Requirements | 14.68 Crore | 49.35% |
| General Corporate Purpose | 6.74 Crore | 22.65% |
Accretion Pharmaceuticals IPO Financial Performance
Find Accretion Pharmaceuticals IPO last 3 years financial details below.
| Financials | 31-Dec-24 (Crores) | 31-Mar-24 (Crores) | 31-Mar-23 (Crores) |
|---|---|---|---|
| REVENUE | 35.75 | 33.94 | 29.53 |
| ASSETS | 39.99 | 27.05 | 20.58 |
| NET WORTH | 13.58 | 5.35 | 3.84 |
| TOTAL DEBT | 13.79 | 13.48 | 8.47 |
| PAT | 5.24 | 3.88 | 0.10 |
Accretion Pharmaceuticals IPO Strengths and Risks
Strengths:
- Certified with ISO 9001:2015, 14001:2015, and 22000:2018 for quality and safety standards
- Operates both in-house manufacturing and contract/loan licensing for corporate clients
- Broad product range including tablets, capsules, syrups, ointments, and medicated cosmetics
- Strong financial growth with PAT up from ₹10.39 lakhs in FY23 to ₹387.53 lakhs in FY24
- Promoters and management have significant experience in pharmaceutical operations
Risks:
- Ongoing legal case related to child labor law violations could impact reputation
- Exposure to interest rate risk on borrowings may affect financial stability
- Promoter group entities operate in a similar line of business, creating potential conflicts of interest
- Business heavily reliant on contract manufacturing, which may face demand variability
- No history of dividend payments may be a concern for income-seeking investors
Accretion Pharmaceuticals IPO Grey Market Premium (GMP)
As of May 14, 2025, the GMP stood at Rs 18, indicating a potential listing price of Rs 119 per share, which is approximately 17.82% higher than the upper end of the price band.
Accretion Pharmaceuticals IPO Review: Apply
Disclaimer: This blog’s content is intended solely for informational and educational purpose only. Before making any investment decisions, it is recommended that investors consult with a certified financial advisor.